Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AGIO with free AI briefings, catalyst countdowns, and dilution alerts.

AGIO · AGIOS PHARMACEUTICALS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$907M Cash on Hand
46.7mo Cash Runway
11% Short Interest
$46.11 Analyst Target (9)
Follow AGIO by email Get an email when AGIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AGIO, unsubscribe in one click. Privacy

📣 What AGIO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Mitapivat (AG-348)
FDA approved Feb 2022 · Pyrukynd
Pyruvate Kinase Deficiency Phase 4 · NCT05777993 Enrolling by invitation
AG-236 Polycythemia Vera Phase 2/3 · NCT07859423 Not yet recruiting
Tebapivat (AG-946) Myelodysplastic Syndromes Phase 2 · NCT05490446 Active not recruiting
Enasidenib Hematologic Neoplasms Phase 1/2 · NCT01915498 Completed
Ivosidenib (AG-120) Chondrosarcoma Phase 2 · NCT04278781 Active not recruiting
[13C2,15N3]-tebapivat Healthy Participants Phase 1 · NCT06745271 Completed
Vorasidenib (AG881) Healthy Volunteers Phase 1 · NCT04128787 Completed
Dihydroorotate Dehydrogenase Inhibitor AG-636 Lymphoma Phase 1 · NCT03834584 Terminated
AG-181 Phenylketonuria Phase 1 · NCT07241234 Recruiting
[14C]-tebapivat Healthy Participants Phase 1 · NCT06745271 Completed
[13C6]AG-348 Healthy Volunteers Phase 1 · NCT03703505 Completed
[13C315N3]AG-881 Healthy Male Participants Phase 1 · NCT03960502 Completed

Also used in these trials (approved or third-party drugs, not AGIO's own candidates): Omeprazole, Rifampin, Midazolam Hydrochloride, Lamotrigine, Itraconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AGIO holds $907M in cash and short-term investments (as of Sep 30, 2026) and burns about $58.3M/quarter from operations, an estimated runway of 46.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AGIO files for a raise →

👥 Who Owns AGIO

Insiders 1.1% Other 5%+ holders 8.6% Institutions (334 holders) 90.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 6,229,199 10.42% 2026-09-30
Farallon Capital Management LLC Institution (13F) 5,939,400 9.93% 2026-09-30
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 5,917,400 9.89% 2026-06-30
Dapice Joshua J. 5%+ holder (13G) 5,159,505 8.63% 2025-12-31
D. E. Shaw & Co., L.P. Institution (13G, 5%+) 3,888,907 6.50% 2026-09-30
Morgan Stanley Institution (13G, 5%+) 3,431,830 5.74% 2026-09-30
STATE STREET CORPORATION Institution (13G, 5%+) 3,108,145 5.20% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 3,088,169 5.16% 2026-03-31
Vanguard Portfolio Management LLC Institution (13F) 2,850,204 4.77% 2026-09-30
Armistice Capital, LLC Institution (13F) 2,578,000 4.31% 2026-09-30
Assenagon Asset Management S.A. Institution (13F) 1,886,412 3.15% 2026-09-30
Brian Goff
Chief Executive Officer, Director · +394,500 options
Insider 184,508 0.31% 2026-04-02

Share count 59,809,651 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-26
filed 2026-10-28
Gheuens Sarah
Option exercise (M) 7,866 $25.01 62,511
2026-10-26
filed 2026-10-28
Gheuens Sarah
Sale (S) 7,866 $37.69 54,645
2026-10-26
filed 2026-10-28
Gheuens Sarah
Option exercise (M) 7,866 – –
2026-10-22
filed 2026-10-23
Gheuens Sarah
Option exercise (M) 500 $25.01 55,145
2026-10-22
filed 2026-10-23
Gheuens Sarah
Sale (S) 500 $37.52 54,645

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-12-07 AQVESME sNDA -31.6% -1.6% -1.7%
2025-09-07 PYRUKYND sNDA -4.5% +1.1% +2.1%

Browse all historical PDUFA outcomes →

Get the full AGIO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AGIO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.